Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Loda

Showing results (331-340 of 409) with videos related to

Pageof 41
Sort By:
Molecular Cancer Research : MCR|February 2, 2022
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate CancerXueliang Gao, Yubao Wang, Caroline F Ribeiro, et al.
Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
Journal of the National Cancer Institute|December 3, 2013
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERGAndreas Pettersson, Rosina T Lis, Allison Meisner, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 24, 2017
Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i>-Defined Prostate CancerRebecca E Graff, Thomas U Ahearn, Andreas Pettersson, et al.
Cancer Cell|September 30, 2020
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19Lars F Westblade, Gagandeep Brar, Laura C Pinheiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Communications|September 6, 2017
Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancerSvitlana Tyekucheva, Michaela Bowden, Clyde Bango, et al.
Cancer Research|June 21, 2018
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic AlterationsAdam G Sowalsky, Huihui Ye, Manoj Bhasin, et al.
Pageof 41

Showing results (331-340 of 409) with videos related to

Sort By:
Pageof 41
Molecular Cancer Research : MCR|February 2, 2022
Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate CancerXueliang Gao, Yubao Wang, Caroline F Ribeiro, et al.
Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.
Journal of the National Cancer Institute|December 3, 2013
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERGAndreas Pettersson, Rosina T Lis, Allison Meisner, et al.
Cancer Discovery|May 29, 2014
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibitionEnrique González-Billalabeitia, Nina Seitzer, Su Jung Song, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 24, 2017
Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i>-Defined Prostate CancerRebecca E Graff, Thomas U Ahearn, Andreas Pettersson, et al.
Cancer Cell|September 30, 2020
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19Lars F Westblade, Gagandeep Brar, Laura C Pinheiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2017
Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate CancerElahe A Mostaghel, Eunpi Cho, Ailin Zhang, et al.
Nature Genetics|September 5, 2020
Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancerAndrea Lunardi, Ugo Ala, Mirjam T Epping, et al.
Nature Communications|September 6, 2017
Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancerSvitlana Tyekucheva, Michaela Bowden, Clyde Bango, et al.
Cancer Research|June 21, 2018
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic AlterationsAdam G Sowalsky, Huihui Ye, Manoj Bhasin, et al.
Pageof 41